Antineutrophil cytoplasmic antibodies: Are they pathogenic?

Clinical and Experimental Rheumatology

Volumn 22, Issue 6 SUPPL., 2004, Pages

  Specks, Ulrich ^a  

^a MAYO CLINIC   (United States)

Author keywords

ANCA; Animal models; Pathogenesis; Vasculitis

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; MYELOBLASTIN;

ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; AUTOIMMUNITY; CAPILLARITIS; CHURG STRAUSS SYNDROME; CROSS REACTION; DISEASE PREDISPOSITION; EDITORIAL; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; WEGENER GRANULOMATOSIS; BINDING AFFINITY; INFLAMMATION; PATHOGENICITY; PROTEIN EXPRESSION; ANIMAL; AUTOIMMUNE DISEASE; CELL CULTURE; DISEASE MODEL; IMMUNOLOGY; PATHOLOGY; VASCULITIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; VASCULITIS;

EID: 15044363676     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (63)

1. DAVIES DJ, MORAN JE, NIALL JF, RYAN GB: Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology. Br Med J 1982; 285: 606.
2. HALL JB, WADHAM BM, WOOD CJ, ASHTON V, ADAM WR: Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust NZ J Med 1984; 14: 277-8.
3. VAN DER WOUDE FJ, RASMUSSEN N, LOBATTO S et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9.
4. JENNE DE, TSCHOPP J, LÜDEMANN J, UTECHT B, GROSS WL: Wegener's autoantigen decoded. Nature 1990; 346: 520.
5. HOFFMAN GS, SPECKS U: Anti-neutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41: 1521-37.
6. FALK RJ, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 25: 1651-7.
7. COHEN TERVAERT JW, GOLDSCHMEDING R, ELEMA JD et al.: Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990; 33: 1264-72.
8. GUILLEVIN L, DURAND-GASSELIN B, CEVALLOS R et al.: Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-30.
9. KEOGH KA, SPECKS U: Churg-Strauss syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115: 284-90.
10. CHOI HK, LAMPRECHT P, NILES JL, GROSS WL, MERKEL PA: Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000; 43: 226-31.
11. CAPIZZI SA, SPECKS U: Does infection play a role in the pathogenesis of pulmonary vasculitis? Semin Respir Infect 2003; 18: 17-22.
12. SHOENFELD Y: Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994; 8: 1296-301.
13. PENDERGRAFT WF 3RD, PRESTON GA, SHAH RR et al.: Autoimmunity is triggered by cPR-3( 105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10: 72-9.
14. CHOI HK, MERKEL PA, WALKER AM, NILES JL: Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high tilers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43: 405-13.
15. MERKEL PA: Drug-induced vasculitis. Rheum Dis Clin North Am 2001; 27: 849-862.
16. KERR GS, FLEISHER TA, HALLAHAN CW, LEAVITT RY, FAUCI AS, HOFFMAN GS: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-371.
17. NOWACK R, GRAB I, FLORES-SUAREZ LF, SCHNULLE P, YARD B, VAN DER WOUDE FJ: ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2001; 16: 1631-7.
18. BOOMSMA MM, STEGEMAN CA, VAN DER LEIJ MJ et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels. A prospective study. Arthritis Rheum 2000; 43: 2025-33.
19. SLOT MC, TERVAERT JW, BOOMSMA MM, STEGEMAN CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-73.
20. GASKIN G, PUSEY CD: Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 2001; 5: 176-81.
21. KLEMMER PJ, CHALERMSKULRAT W, REIF MS, HOGAN SL, HENKE DC, FALK RJ: Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42: 1149-53.
22. KEOGH KA, WYLAM ME, STONE JH, SPECKS U: Induction of remission in 11 patients with refractory ANCA-associated vasculitis by B lymphocyte depletion. Arthritis Rheum 2004; 50 (in press).
23. RUSSELL KA, SPECKS U: Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. Rheum Dis Clin North Am 2001; 27: 815-32.
24. SAVAGE CO, HARPER L, HOLLAND M: New findings in pathogenesis of antineutrophil cytoplasm antibody- associated vasculitis. Curr Opin Rheumatol 2002; 14: 15-22.
25. HEERINGA P, TERVAERT JW: Pathophysiology of ANCA-associated vasculitides: Are ANCA really pathogenic ? Kidney Int 2004; 65: 1564-7.
26. NASSONOV EL, SAMSONOV MY, TILZ GP et al.: Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheumatol 1997; 24: 666-70.
27. JONASDOTTIR O, PETERSEN J, BENDTZEN K: Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis. APMIS 2001; 109: 781-6.
28. CSERNOK E, ERNST M, SCHMITT W, BAINTON DF, GROSS WL: Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95: 244-50.
29. WITKO-SARSAT, V, LESAVRE P, LOPEZ S et al.: A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999; 10: 1224-33.
30. RAROK AA, STEGEMAN CA, LIMBURG PC, KALLENBERG CG: Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13: 2232-8.
31. SCHREIBER A, BUSJAHN A, LUFT FC, KETTRITZ R: Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003; 14: 68-75.
32. REUMAUX D, DE BOER M, MEIJER AB, DUTHILLEUL P, ROOS D: Expression of myeloperoxidase (MPO) by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies (ANCA) against MPO. J Leukoc Biol 2003; 73: 841-9.
33. STEGEMAN CA, COHEN TERVAERT JW, SLUITER WJ, MANSON WL, DE JONG PE, KALLENBERG CGM: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-7.
34. ABDEL-SALAM B, IKING-KONERT C, SCHNEIDER M, ANDRASSY K, MANSCH GM: Autoantibodies to neutrophil cytoplasmic antigens (ANCA) do not bind to polymorphonuclear neutrophils in blood. Kidney Int 2004; 66: 1009-17.
35. HARPER L, REN Y, SAVILL J, ADU D, SAVAGE CO: Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages. Am J Pathol 2000; 157: 211-20.
36. DONALD KJ, EDWARDS RL, McEVOY JDS: An ultrastructural study of the pathogenesis of tissue injury in limited Wegener's granulomatosis. Pathology 1976; 8: 161-9.
37. MOOSIG F, CSERNOK E, KUMANOVICS G, GROSS WL: Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-alpha). Clin Exp Immunol 2000; 122: 499-503.
38. HARPER L, COCKWELL P, ADU D, SAVAGE CO: Neutrophil priming and apoptosis in antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int 2001; 59: 1729-1738.
39. GILLIGAN HM, BREDY B, BRADY HR et al: Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 1996; 184: 2231-41.
40. YANG JJ, TUTTLE RH, HOGAN SL et al.: Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin Exp Immunol 2000; 121: 165-72.
41. KINJOH K, KYOGOKU M, GOOD RA: Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vesel vasculitis. Proc Natl Acad Sci USA 1993; 90: 3413-7.
42. HARPER JM, THIRU S, LOCKWOOD CM, COOKE A: Myeloperoxidase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL/Mp-Ipr/Ipr mice: a spontaneous model for human microscopic angiitis. Eur J Immunol 1998; 28: 2217-26.
43. MATHIESON PW, THIRU S, OLIVEIRA DB: Mercuric chloride-treated brown Norway rats develop widespread tissue injury including necrotizing vasculitis. Lab Invest 1992; 67: 121-9.
44. ESNAULT VL, MATHIESON PW, THIRU S, OLIVEIRA DB, MARTIN-LOCKWOOD C: Autoantibodies to myeloperoxidase in brown Norway rats treated with mercuric chloride. Lab Invest 1992; 67: 114-20.
45. BROUWER E, HUITEMA MG, KLOK PA et al.: Anti-myeloperoxidase associated proliferative glomerulonephritis; an animal model. J Exp Med 1993; 177: 905-14.
46. 2 in myeloperoxidae-immunized rats leads to necrotizing vasculitis in the lungs and gut. Am J Pathol 1997; 151: 131-9.
47. FOUCHER P, HEERINGA P, PETERSEN AH et al.: Antimyeloperoxidase-associated lung disease. An experimental model. Am J Respir Crit Care Med 1999; 160: 987-94.
48. YANG JJ, JENNETTE JC, FALK RJ: Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 1994; 97: 466-473.
49. BROUWER E, KLOK PA, HUITEMA MG, WEENING JJ, KALLENBERG COM: Renal ischemia/reperfusion injury contributes to renal damage in experimental anti-myeloperoxidae-associated proliferative glomerlonephritis. Kidney Int 1995; 47: 1121-9.
50. KOBAYASHI K, SHIBATA T, SUGISAKI S: Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995; 47: 454-63.
51. HEERINGA P, BROUWER E, KLOK PAGHM, VAN DEN BORN L, WEENING JJ, KALLENBERG CGM: Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement- membrane mediated glomerular injury. Am J Pathol 1996; 149: 1695-706.
52. XIAO H, HEERINGA P, HU P et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-63.
53. PFISTER H, OLLERT M, FROHLICH LF et al.: Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004; 104: 1411-8.
54. FRANSSEN CF, GANS RO, ARENDS B et al.: Differences between anti-myeloperoxidase-and anti-proteinase 3-associated renal disease. Kidney Int 1995; 47: 193-9.
55. HOGAN SL, NACHMAN PH, WILKMAN AS, JENNETTE JC, FALK RJ: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 23-32.
56. BOOTH AD, ALMOND MK, BURNS A et al.: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-84.
57. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
58. HOLLAND M, HEWINS P, GOODALL M, ADU D, JEFFERIS R, SAVAGE CO: Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol 2004; 138: 183-92.
59. RUSSELL KA, FASS DN, SPECKS U: Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2001; 44: 463-468.
60. REUMAUX D, DUTHILLEUL P, NAUSEEF WM, ROOS D: Pro-myeloperoxidase, a target antigen for antineutrophil cytoplasm autoan tibodies: comment on the article by Russell et al. Arthritis Rheum 2002; 46: 1127-9.
61. SOMMARIN Y, RASMUSSEN N, WIESLANDER J: Characterization of monoclonal antibodies to proteinase 3 and application in the study of epitopes for classical anti-neutrophil cytoplasm antibodies. Exp Nephrol 1995; 3: 249-56.
62. VAN DER GELD YM, TOOL AT et al.: Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis. Clin Exp Immunol 2002; 129: 562-70.
63. LAKGFORD CA: Antineutrophil cytoplasmic antibodies should not be used to guide treatment in Wegener's granulomatosis. Clin Exp Rheumatol 2004; 22 (Suppl. 36): S3-S6.